The Hidden Inspection Risk in Your Medical and Safety Review Workflow
You have just been told an inspection is coming. Your team’s first reaction is not to prepare the science. It is to reconstruct the paper trail. Finding the review notes. Tracing which queries were raised and when. Confirming what decisions were made across which studies, in which systems, by which reviewers. For many organizations, medical and safety review produces excellent clinical judgment. What it often does […]
Why Medical and Safety Review Is One of the Last Manual Workflows in Clinical Trials
It is Tuesday morning. You have a data cut from last night, three studies to review before end of week, and a patient-level safety flag that needs an answer before this afternoon’s call with the sponsor. So you open the EDC, pull the adverse event listing, cross-reference the lab data in a separate system, check the concomitant medications in a third, and start […]
Turning Oversight into Evidence: How to Prove Your Decisions at Any Point in a Trial
Clinical trial oversight is changing. For years, Sponsors have focused on demonstrating that oversight activities occurred: monitoring visits were completed, risks were reviewed, issues were escalated, and actions were documented. While these activities remain critical, evolving regulatory expectations, from ICH E6(R3) to EMA guidance on audit trail review, are shifting the conversation toward a more […]
Inspection Readiness Is About Traceability, Not Documentation
Inspections have evolved. What matters most today isn’t the volume of documentation, but the clarity of oversight logic. What Inspectors Expect to Understand Inspectors increasingly focus on: Why certain risks were prioritized How oversight strategies were chosen What actions were taken when signals emerged How outcomes were verified This requires traceability, not reconstruction. RBQM Done […]
RBQM in Practice: From Principles to Proportionate Oversight
Regulatory guidance clearly defines what RBQM is intended to achieve. The harder question is how those principles translate into daily oversight decisions. This is where many RBQM programs struggle. CtQs Are Necessary—But Not Sufficient Critical-to-Quality (CtQ) factors anchor modern RBQM. They define what truly matters to participant safety and data reliability. But CtQs only create […]
What Sponsors Actually Look for in CRO RBQM
And why inspection readiness is now a commercial differentiator. RBQM is often discussed as a regulatory requirement. But for CROs, it has become something more. It’s now a factor in how Sponsors select partners, evaluate performance, and decide where to expand or reduce scope. Understanding what Sponsors are actually looking for requires looking beyond the […]
From Fragmentation to a Scalable RBQM Operating Model
Why tools alone aren’t enough, and what CROs need instead. Most CROs don’t lack RBQM capability. They have invested in centralized monitoring. They have access to data. They have systems that can surface signals and identify outliers across studies. And yet, execution remains inconsistent. The issue isn’t visibility. It’s coordination. Why Fragmentation Persists In many […]
Monitoring Isn’t a Cost Problem. It’s a Margin Lever.
Why CROs need to rethink monitoring, not reduce it. For years, the conversation around monitoring has been framed in terms of cost. How many visits are we doing? How much SDV is required? Where can we reduce effort without increasing risk? Those questions made sense in a model where monitoring focused primarily on coverage, ensuring […]
Why RBQM Fails at Scale in CROs
Most CROs don’t lack RBQM capabilities. They lack a model to execute it consistently. Most CROs today would say they’re doing RBQM. They have centralized monitoring in place. They track KRIs and QTLs. They review data regularly and can identify emerging risks across studies. From a capability standpoint, the foundation is in place. And yet, […]
ICH E6(R3), Demystified Part 4: Informed Consent
From Signature to System: Why E6(R3) Raises the Bar For years, informed consent has too often been treated as a regulatory artifact, a document to be signed, filed, and archived. ICH E6(R3) quietly but decisively challenges that mindset. The revision does not radically rewrite the rules of informed consent. Instead, it does something more powerful: it […]
